The Cannigma
JUNE 14, 2021
All that is about to change, thanks to a change at the DEA , which cultivators and industry experts say will be monumental for cannabis research, medical marijuana patients, and potentially the broader legal status of the plant itself. “We Junk’ cannabis ‘ill-suited for clinical trials’. BRC) told The Cannigma this week.
Cannabis Law Report
MARCH 30, 2022
Senate Bill 253: The Cannabidiol and Marihuana Research Expansion Act provides the office of US Attorney General, rather than the US Drug Enforcement Administration, the discretion to license scientists to engage in clinical trials involving the use of cannabis by human subjects. Senate members in 2020 passed a similar version of S.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veriheal
AUGUST 31, 2020
It brings us great pleasure to present the 10 winners of Veriheal’s Innovation in Cannabis Scholarship 2020. Veriheal’s Innovation in Cannabis Scholarship 2020 Winners . The post Veriheal’s Innovation in Cannabis Scholarship 2020 Winners appeared first on Cannabis Central. Nishtha Tripathi. School: George Washington University.
Cannabis Law Report
FEBRUARY 10, 2022
Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). By Allison Campbell.
NewsMunchies
NOVEMBER 12, 2021
In clinical trials, psilocybin (the psychoactive substance in mushrooms) has shown tremendous promise in treating severe depression, post-traumatic stress disorder, and other mental illnesses. Additional clinical trials underway in the U.S. While the science on psychedelics is exploding, there are roadblocks in the way.
SpeedWeed
JULY 23, 2021
When you’re talking about wanting to do an actual clinical trial, you need a diversity of people that participate and one state just does not have the diversity of people that are required,” Towle said. Back in 2020, the company was granted the first Colorado cannabis research license to study dementia. “The
Cannabis Law Report
MAY 29, 2022
In 2020, Oregon became the first locale to decriminalize psilocybin and legalize it for therapeutic use on a statewide basis. 8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. Clinical Trials and Human Subject Protections. DEA and the Controlled Substances Act.
Expert insights. Personalized for you.
133 
Let's personalize your content